发明公开
EP2951202A2 HIGH AVIDITY BINDING MOLECULES RECOGNIZING MAGE-A1
审中-公开
MAGE-A1 ERKENNENDEBINDUNGSMOLEKÜLEMIT HOHERAVIDITÄT
- 专利标题： HIGH AVIDITY BINDING MOLECULES RECOGNIZING MAGE-A1
- 专利标题（中）： MAGE-A1 ERKENNENDEBINDUNGSMOLEKÜLEMIT HOHERAVIDITÄT
-
申请号： EP14702238.8申请日： 2014-01-29
-
公开(公告)号： EP2951202A2公开(公告)日： 2015-12-09
- 发明人: BLANKENSTEIN, Thomas , OBENAUS, Matthias , LEITAO, Catarina
- 申请人： Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch;
- 申请人地址： Robert-Rössle-Strasse 10 13092 Berlin DE
- 专利权人： Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch;
- 当前专利权人： Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch;
- 当前专利权人地址： Robert-Rössle-Strasse 10 13092 Berlin DE
- 代理机构： Krauss, Jan
- 优先权： EP13153081 20130129
- 国际公布： WO2014118236 20140807
- 主分类号： C07K14/725
- IPC分类号： C07K14/725 ; C07K16/30 ; A61K39/395 ; C12N15/13 ; C12N15/12 ; A61P35/00
摘要：
The present invention pertains to novel high avidity antigen recognizing constructs, such as antibodies or T cell receptors, which specifically bind to the melanoma associated antigen (MAGE) A1. The constructs of the invention are particularly useful for the diagnosis, prevention or therapy of tumorous diseases which are characterized by the specific expression of the MAGE-A1 antigen. Furthermore provided are nucleic acids, vectors and host cells—such as CD4 or CD8 positive T cells—which encode, comprise or present the antigen recognizing constructs of the invention. The invention thus provides new means for immune therapy, specifically adoptive T cell therapy, for treating cancer.
公开/授权文献
- EP2951202B1 HIGH AVIDITY BINDING MOLECULES RECOGNIZING MAGE-A1 公开/授权日：2020-04-08
信息查询
